Respiratory movement and pain thresholds in airway environmental sensitivity, asthma and COPD  by Johansson, Ewa-Lena et al.
Respiratory Medicine (2012) 106, 1006e1013Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedRespiratory movement and pain thresholds in
airway environmental sensitivity, asthma and COPDEwa-Lena Johansson a, Ewa Ternesten-Hasse´us b, Monika Fagevik Olse´n a,
Eva Millqvist b,*aDepartments of Clinical Neuroscience and Rehabilitation, Physiotherapy, the Sahlgrenska Academy,
University of Gothenburg, Sweden
bDepartment of Internal Medicine/Respiratory Medicine and Allergology, the Sahlgrenska Academy,
University of Gothenburg, Sweden
Received 1 November 2011; accepted 15 March 2012
Available online 15 April 2012KEYWORDS
Asthma;
COPD;
Sensory
hyperreactivity;
Chest mobility;
Respiratory
movement;
Pain sensitivity* Corresponding author. Departmen
Gothenburg, Sweden. Tel.: þ46 708 4
E-mail address: eva.millqvist@med
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2012.03.011Summary
Introduction: Patients with “sensory hyperreactivity” (SHR) have airway environmental sensi-
tivity, chronic cough and dyspnoea. Cough, chest discomfort and sense of difficulties getting
air are some of the symptoms these patients seek medical attendance for. The patients have
increased cough sensitivity to inhaled capsaicin, mediated by ion channel receptors on sensory
nerves also known to react to pain stimuli. Whether a link exists between capsaicin airway sensi-
tivity and pain sensitivity has not yet been evaluated. The aim was to investigate chest mobility,
respiratory movement and pain sensitivity in SHR patients compared with patients with asthma,
chronic obstructive pulmonary disease (COPD) and alleged healthy control subjects.
Methods: Thirty-five patients diagnosed with SHR, 19 with COPD, 32 with asthma and 28 control
subjects were included. Chest expansion was measured with a measuring tape and thoracic and
abdominalmovementwith light sensors. Pain sensitivitywasassessedusing apressure algometer.
Results: Groups differed significantly in lung function, respiratory rate and pain sensitivity but
also in chest expansion and abdominal breathing movement. In comparison with the control
and asthma groups but not the COPD patients, SHR patients had an increased respiratory rate
and reduced abdominal movement during deep breathing. All patient groups showed lower pain
thresholds than the controls.
Conclusion: Patients with SHR have evident signs of dysfunctional breathing and appeared to be
most similar to the COPD group except for lung function. Lower pain thresholds among the
patients indicate a general up-regulation of the sensory nerve system.
ª 2012 Elsevier Ltd. All rights reserved.t of Allergology, the Sahlgrenska Academy, University of Gothenburg, Bruna Stra˚ket 11A, S-413 45
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Breathing pattern and pain sensitivity in airway diseases 1007Introduction The aim of this study was to investigate chest mobility,Patients with airway symptoms induced by environmental
irritants report problems with persistent coughing, chest
discomfort and dyspnoea.1,2 These symptoms mimic asthma,
but asthma-specific tests are negative and lung function tests
arewithin normal range.Thepatients havean increased cough
reaction to inhaled capsaicin, a tasteless and odorless
substance that stimulates sensory nerves and reflects sensory
nerve reactivity.3 Such airway symptoms are interpreted as
airway sensory hyperreactivity (SHR). Cigarette smoke, car
exhaust and perfumed products are some of the triggers for
SHR symptoms.1,2 In most cases, the patients could also be
diagnosed with chronic cough4,5 or cough hypersensitivity
syndrome.6,7 SHR affectsmore than 6% of the adult population
in Sweden, mainly women, according to a population-based
epidemiologic study8 where SHR diagnosis was based on
a validated questionnaire, the chemical sensitivity scale for
sensory hyperreactivity (CSS-SHR), in combination with
a standardized positive capsaicin inhalation provocation
test.9,10 This inhalation test has a good repeatability and
ability to distinguish patients with SHR from healthy control
subjects.1,11
In recent years, there has been a growing interest in the
family of transient receptor potential (TRP) ion channels in
airway diseases.12,13 They are an important means for
multiple organ systems to interact with their environ-
ment.14 Because the transient receptor potential vanilloid
subtype 1 (TRPV1), which is responsible for the increased
capsaicin cough response in SHR, is also known to react to
pain stimuli and mirror pain sensitivity,15 we hypothesize
that SHR patients may have a corresponding augmented
sensitivity to pain.
Complains about dyspnoea, though normal lung function
and uncharacteristic chest pain are common in SHR.1,2
Discomfort, pain, or sense of trouble in the body or parts
of the body, in this case the chest, could, through the
sensory feedback to the brain, lead to increased tonus of
the musculature. Heavy breathing, sense of dyspnoea and
decreased chest mobility may lead to dysfunctional
breathing and follow this vicious circle of pain, increased
tonus, and even more pain.16e18 Dysfunctional breathing as
an explanation for similar symptoms has been suggested by
Hagman et al19,20 but a difference in comparison to SHR is
that environmental irritants as trigger factors are not
described. Whether patients with SHR have dysfunctional
respiratory movement and/or impaired chest mobility in
relation to the reported symptoms of chest tightness and
dyspnoea has not yet been evaluated.
Respiratory movement dysfunction as a consequence of
impaired chest mobility is shown in different respiratory and
chest diseases, such as after thoracic surgical proce-
dures,21,22 in ankylosing spondylitis23 and in patients with
persistent asthma, who had musculoskeletal dysfunction
and chronic pain that was independent of the severity of
their disease.24 In severe COPD the breathing pattern
seemed to be dependent of the inspiratory muscle activity25
and when studying the breathing pattern in such patients,
using a respiratory inductive plethysmography, Tobin et al
found high respiratory rate, short inspiratory time and an
asynchrony between ribcage and abdominal movements.26respiratory movement, and sensitivity to pain in SHR
patients in comparison to patients with well-defined
asthma and COPD and to alleged healthy control subjects.
Methods
Subjects
The patients were consecutively selected from the asthma
and allergy outpatient clinic at Sahlgrenska University
Hospital in Gothenburg, Sweden during 2009 and 2010.
Thirty-five patients clinically diagnosed with SHR, 19 with
COPD and 32 with asthma participated in the study.
Twenty-eight control subjects were included; they
considered themselves healthy, reported no airway symp-
toms and did not use airway-related drugs. No further
physical examination was assessed. The control subjects
were recruited from hospital workers, friends and
relatives.
The SHR patients all had pronounced airway symptoms
induced by environmental irritants and a positive capsaicin
inhalation cough test, performed in accordance with
several earlier studies.8,10 The capsaicin test was per-
formed with an interval of at least six weeks after any
respiratory tract infection. All but one of the patients with
SHR had also complained of daily or weekly problems with
coughing for more than two months and could additionally
have been diagnosed with chronic cough.4,5 They further
had a negative skin prick test (SPT) that tested ten of the
most common respiratory allergens in Sweden, a negative
methacholine test in accordance with international guide-
lines27,28 and no signs of spirometric reversibility or vari-
ability in lung function.
The patients with asthma and COPD were diagnosed
according to international guidelines.29,30 Seventeen
asthma patients used a combination of inhaled corticoid
steroids and long acting b2 agonists (ICS þ LABA), 8 used ICS
and LABA separately, 6 used ICS and all 32 asthma patients
used short acting b2 agonists, when needed. Twenty of the
32 asthma patients had previously shown a positive SPT to
at least one allergen and all had a positive methacholine
test.27,28 Amongst the 19 COPD patients 16 regularly used
ICS, 15 long acting anti cholinergic (LAAC) and 18 short
acting b2 agonists when needed. All COPD patients were
former smoker.
Patients diagnosed with SHR, asthma or COPD consid-
ered themselves to have a habitual condition, medicating
according to instructions from their physicians and with no
ongoing airway infection or any change in the use of
medication from four weeks prior to study participation.
There were no changes in use of airway-related medica-
tions before the tests. The participants reported no symp-
toms of gastro-oesophageal reflux and were not allowed to
take any medication for such symptoms. Use of angiotensin-
converting enzyme inhibitors, diseases or injuries affecting
the thoracic range of motion, pregnancy and breastfeeding
were exclusion criteria. Active smokers were not included.
Informed consent was obtained from all participants at
the start of the investigation. The Regional Ethical Review
Board of Gothenburg approved the study.
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Each participant visited the clinic on one occasion to
measure chest mobility, respiratory movement, pressure
pain thresholds and lung function. They were also regis-
tered according to smoking habits and body mass index
(BMI). The patient groups were not blinded to the special-
ized physiotherapist who performed all measurements.
Chest mobility
Chest mobility (in cm) was assessed with a measuring tape
as chest expansion, thoracic flexion and extension. Chest
expansion was measured as the circumference difference
after maximal inhalation through the nose and maximal
exhalation through the mouth at the level of the xiphoid
process with participants in a standing position with their
hands on their head. Thoracic flexion and thoracic exten-
sion were measured 30 cm distally from the seventh
cervical vertebrae (C7) in a standing position with the
patient’s hands along their sides.31e33 Every measurement
was performed three times, and the best of the three
measurements was noted in accordance with an earlier
described method.34
Respiratory movement
Respiratory movement (in mm) was recorded with the
respiratory movement-measuring instrument (RMMI) (ReMo
Inc. Keldnaholt, Reykjavik, Iceland).35,36 The measure-
ments, registered as real-time bilateral changes in anterior
posterior diameter, included upper and lower thoracic and
abdominal movement at quiet and deep breathing as well
as breathing frequencies at quiet breathing. The RMMI
consists of a mobile rack and two parallel distance adjust-
able rods holding six laser distance sensors (diodes) with an
accuracy of 0.0003 mm, a light precision of 0.2 mm and
a measuring frequency of 21 Hz (Senix Ultra-U revision B;
Senix, Bristol, Vt., USA). The diodes are attached to the
rods in parallel pairs, and the upper and lower pairs of
diodes are individually adjustable to match differences in
chest length. The data acquisition system (an NI UCB AD
converting unit) converted data from analogue to digital
signals and transmitted the signals to a specially designed
PC program. In accordance with previous studies the
participants were placed in a supine position on a treat-
ment bench with a small pillow under their head and
knees.21e23 They were told to relax and close their eyes
during the measurements. The secured parallel pairs of
diodes were placed at the level lateral to each individual’s
xiphoid process. The adjustable parallel upper thoracic and
abdominal pairs were placed at a line between each indi-
vidual’s frontal armpit folds and at a level lateral to each
individual’s umbilicus, respectively. The transversal
distance between the diodes attached to the rods was
12 cm. The rods were fixed at a height from the body
surface where the green lights on each diode indicated the
optimal position. During the deep-breathing manoeuvre,
the participants were instructed to inhale through their
nose and exhale through their mouth without holding their
breath between inhalation and exhalation. After thoroughinstructions, data were collected during 1 min for the tidal
breathing and during 30 s for the deep breathing
manoeuvre. The patients were not aware of when during
the performance the data were recorded. All data were
manually transferred into an Excel file and saved for
analysis.
Pain sensitivity
Pain sensitivity was evaluated by pressure pain thresholds
(PPT) for measuring and quantifying deep tenderness in
muscles. The Somedic algometer (Somedic AB, BOX 194, SE
24222 Ho¨rby Sweden) is a gun-shaped handle creating
pressure through a pressure sensitive strain gauge at the
tip, connected to a power supply, an amplifier and a display
unit.37,38 The display shows the actual pressure given (kPa/
s), and a scale indicates the rate of pressure to help the
examiner to keep the pressure constant. With the patient in
a seated position, pressure was applied two times at five
bilateral points of the body: At two distal points, the distal
thumb phalangeal and the gracilis muscle tendon at the
inside of the knee. Further at three points at the chest, the
costae II, distal of the midst part of the clavicle, the
supraspinous muscle and the trapezius muscle’s second
portion, between the angulus superior at scapulae and the
vertebral column, in accordance with earlier studies.37,38
When the participant reported that pressure changed to
pain, the pressure was stopped, and the mean value of the
two tests was documented.
Spirometry
Each participant performed a spirometry with a portable
ultrasonic spirometer (Easy One ndd, Medical Technologics,
Switzerland) that measured the forced expiratory volume in
1 s (FEV1) and the forced ventilatory capacity (FVC). The
results are given as % of the predicted value for each
individual according to gender, age and body length.28
Statistical analysis
For categorical variables, number (n) and percentage (%)
are presented, and for continuous variables, the mean and
standard deviation (SD) are presented. For comparisons
between groups, the Chi Square test was used for non-
ordered categorical variables, and the KruskaleWallis test
was used for continuous variables. For pair wise comparison
between groups the Fisher’s Exact test was used for
dichotomous variables and the ManneWhitney U-test for
continuous variables.
Results
Characteristics of the three patient groups and the control
subjects are shown in Table 1.
In accordance with international guidelines,30 four of
the COPD patients were classified as having COPD with
moderate severity (FEV1 50e80% of predicted value), 11
were classified with severe COPD (FEV1 30e50% predicted)
and 4 with very severe COPD (FEV1< 30% predicted). The
Table 1 dCharacteristics of patients and control subjects. Test between groupsdP value.
Variable SHR
(n Z 35)
Asthma
(n Z 32)
COPD
(n Z 19)
Controls
(n Z 28)
P
value
SHR vs
controls
SHR vs
asthma
SHR vs
COPD
Asthma vs
controls
Asthma vs
COPD
CPOD vs
controls
Gender
Female 31
(88.6%)
28
(87.5%)
17
(89.5%)
22
(78.6%)
Male 4
(11.4%)
4
(12.5%)
2
(10.5%)
6
(21.4%)
0.6 0.5 1.0 1.0 0.6 1.0 0.6
Age (years) 50.7
(10.0)
49.1
(8.1)
63.9
(5.8)
51.5
(9.1)
<0.001 0.9 0.3 <0.001 0.3 <0.001 <0.001
BMI (kg/m2) 25.6
(4.5)
26.9
(5.6)
23.1
(4.7)
24.3
(3.0)
0.06 0.3 0.3 0.1 <0.05 <0.05 0.3
Smoking
Former 15
(42.9%)
12
(37.5%)
19
(100%)
15
(53.6%)
Never 20
(57.1%)
20
(62.5%)
0
(0%)
13
(46.4%)
<0.001 0.6 0.8 <0.001 0.3 <0.001 <0.0005
FVC % pred. 103.7
(16.3)
104.7
(16.5)
75.2
(19.7)
109.7
(9.5)
<0.001 0.1 0.9 <0.001 0.2 <0.001 <0.001
FEV1 % pred. 98.4
(17.2)
91.6
(15.8)
42.7
(17.9)
100.3
(8.2)
<0.001 0.6 0.1 <0.001 <0.05 <0.001 <0.001
For categorical variables, number (n) and percentage (%) are presented, and for continuous variables, the mean and standard deviation
(SD) are presented. For comparisons between groups, the Chi Square test was used for non-ordered categorical variables, and the
KruskaleWallis test was used for continuous variables. For pair wise comparison between groups the Fisher’s Exact test was used for
dichotomous variables and the ManneWhitney U-test for continuous variables. Significant values are highlighted in grey.
Breathing pattern and pain sensitivity in airway diseases 1009COPD group was significantly older, had smoked more and
had impaired predicted FEV1 % and predicted FVC % in
comparison to the other patient groups and the controls.
Compared with the control subjects and COPD patients, the
asthma group had a higher BMI. Furthermore, the asthmatic
patients had lower predicted FEV1 % compared with the
control group.
The four groups differed significantly in chest expansion,
respiratory rate, lower thoracic and abdominal movement
at quiet breathing, abdominal movement at deep breathing
and in pain pressure thresholds at central points (Table 2).
For the RMMI, only results from the right side of body are
shown since there were no side differences, which is in
accordance with earlier findings.36Chest mobility
The COPD patients had lower expansion ability than the
other three groups, whereas the SHR patients had reduced
values compared with the controls (Table 2). The COPD
patients also had lower thoracic flexion values compared
with the asthma group and the controls as well as lower
thoracic extension ability compared with control subjects.
In the control group, the results of chest mobility regarding
expansion, thoracic flexion and extension were within
Swedish reference values.34Respiratory rate
The SHR and COPD patients had a higher respiratory rate
at rest than the asthma patients and control subjects,whereas the SHR and COPD groups did not differ from each
other (Table 2).
Respiratory movement
During quiet breathing, values of lower thoracic and
abdominal movement were higher among COPD and asthma
patients compared with the SHR group (Table 2). In the
COPD group, these values were also higher than the
controls’. During deep breathing, the abdominal movement
values were lower in the SHR group than among asthma
patients and control subjects (Fig. 1), whereas in the COPD
group, the abdominal and lower thoracic movement values
were lowered only compared with the control group.
Pain sensitivity
The pain pressure thresholds at central points were lower in
all three patient groups compared with the control
subjects, and for the SHR group the pain threshold was also
lower at m. Gracili’s tendon (Table 2).
Discussion
The main findings of this study are that respiratory rate was
increased and chest mobility and breathing movement were
impaired in patients with SHR and COPD but not in patients
with asthma compared with a control group without any
airway symptoms. The SHR patients appeared to have the
most similarities with the COPD group, comprising mainly
patients who were severely or very severely affected by the
Table 2 dResults of chest mobility, respiratory rate, respiratory movements and pain Thresholds. Test between groupsdP value.
Variable SHR
(n Z 35)
Asthma
(n Z 32)
COPD
(n Z 19)
Controls
(n Z 28)
P value SHR vs
controls
SHR vs
asthma
HR vs
OPD
Asthma vs
controls
Asthma vs
COPD
COPD vs
controls
Chest mobility (cm)
Expansion 4.6 (1.6) 4.9 (2.2) 3.1 (1.6) 5.7 (2.0) <0.0005 <0.05 0.8 0.005 0.2 <0.001 <0.001
Thoracic flexion 2.2 (0.9) 2.4 (0.9) 1.7 (0.7) 2.3 (1.1) 0.09 0.7 0.5 0.06 0.8 <0.05 <0.05
Thoracic extension 2.8 (1.5) 2.8 (1.3) 2.24 (1.1) 3.1 (1.5) 0.2 0.3 0.9 0.2 0.4 0.1 <0.05
Quiet breathing
Respiratory rate/min 14.3 (4.0) 11.6 (2.8) 15.0 (3.0) 11.8 (3.6) <0.001 <0.05 <0.01 0.4 0.9 0.001 <0.005
Respiratory movements (mm)
Upper thoracic 3.2 (1.4) 3.6 (1.6) 3.7 (1.2) 4.1 (2.9) 0.3 0.1 0.2 0.1 0.7 0.6 0.8
Lower thoracic 3.6 (1.7) 4.1 (1.3) 4.8 (1.7) 4.1 (2.5) <0.05 0.6 <0.05 0.01 0.2 0.2 <0.05
Abdominal 6.0 (3.0) 7.8 (2.7) 8.5 (2.4) 7.3 (3.3) <0.005 0.08 <0.01 0.001 0.3 0.3 <0.05
Deep breathing
Respiratory movements (mm)
Upper thoracic 12.9 (5.1) 14.5 (6.1) 13.4 (4.8) 15.8 (6.3) 0.3 0.07 0.3 0.6 0.4 0.7 0.2
Lower thoracic 10.1 (4.2) 11.2 (5.5) 8.9 (3.0) 12.5 (5.3) 0.1 0.09 0.6 0.5 0.2 0.2 <0.05
Abdominal 11.1 (4.8) 13.8 (4.0) 12.0 (4.1) 16.3 (6.5) <0.001 <0.0001 <0.005 0.3 0.1 0.2 <0.05
Pain thresholds (Kpa/s)
Distal thumb
phalange
346.7 (122.9) 396.8 (136.9) 374.9 (125.0) 409.4 (139.4) 0.3 0.08 0.2 0.5 0.6 0.5 0.3
Costa II 205.4 (69.2) 200.9 (62.8) 204.7 (72.3) 255.6 (73.3) <0.05 <0.01 0.9 0.9 <0.005 1.0 <0.05
M. Supraspinatus 303.6 (109.6) 333.2 (132.6) 315.9 (113.8) 418.1 (115.9) <0.005 <0.001 0.4 0.9 <0.05 0.5 <0.005
M. Trapezius 290.2 (85.7) 345.4 (131.4) 344.9 (125.4) 425.8 (133.1) <0.005 <0.0005 0.1 0.1 <0.05 0.9 0.07
M. Gracili’s tendon 269.9 (104.8) 287.2 (103.6) 315.6 (146.6) 355.5 (131.8) 0.07 <0.01 0.3 0.5 0.06 1.0 0.2
For continuous variables Mean (SD) is presented. For comparison between groups KruskaleWallis test was used for continuous var bles. For pair wise comparison between groups
ManneWhitney U-test was used for continuous variables. Significant values are highlighted in grey.
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Figure 1 Box-plot presentation of abdominal movements at
deep breathing in 35 patientswith SHR, 32 patients with asthma,
19 patients with COPD and 28 control subjects. Five horizontal
lines on each box graph (from bottom to top) represent the 10th,
25th, 50th (median), 75th, and 90th percentiles.
Breathing pattern and pain sensitivity in airway diseases 1011disease. Furthermore, all three patient groups had
increased sensitivity to pain as assessed by pressure
algometry.
The COPD patients were older and had lower BMI than
the other patient groups, and this may probably mirrors the
patient selection at the Sahlgrenska University Hospital.
Patients with COPD attending the hospital have mostly
a severe form of disease, developed with increasing age
and followed by low BMI in accordance with earlier
reports.39,40
Chestmobilitywasmeasured as chest expansion, thoracic
flexion and extension in cm with a measuring tape. This is
a cheap, easy, effortless and reproducible method
commonly used in everyday physiotherapeuticwork to assess
the status and treatment effects in various diagnoses of the
chest.34 The current results emphasize the importance of
this method as a simple way to estimate diversities between
patient groups and outcomes of physiotherapeutic treat-
ment. The RMMI, on the other hand, is a relatively new
method for measuring respiratory movement. This method
has been evaluated and has been found to be a reliable and
sensitive instrument with high reproducibility, for detecting
even very small changes in thoracic movement during
breathing.23,35,36 For this study, the RMMI was chosen
because of its accuracy, accessibility and an interest in
detecting and objectifying the symptoms of dyspnoea and
chest discomfort that SHR patients often report.1,2 There are
other options for measuring breathing patterns and ribcage
movement; with a body box or with inductive plethysmog-
raphy, but these equipments require advanced laboratory
resources why the more simple method of RMMI was used.
Chest pain and discomfort are common symptoms in
SHR,1,2 like in asthma and COPD, though such studies are
relatively sparse and mainly based on interviews.24,41e43
Pain is difficult to measure and quantify because it is by
nature a subjective experience. PPT is a semi-objective
method for measuring deep tenderness in muscles and
quantifying pain and is considered to be stable according torepeatability in intra-individual measurements with good
reproducibility.37,38 The lowered pain thresholds among all
three patient groups may be an expression of a general up-
regulation of TRP channels throughout the sensory nerve
system, consistent with earlier reports of increased
capsaicin cough sensitivity in SHR, COPD and asthma.1,44e47
Meeting a patient having symptoms difficult to explain
by established medical science is often a challenge for the
physician and the physiotherapist. Because SHR patients
are mostly characterized by normal lung function, the
frequently pronounced breathing and chest symptoms
described by patients have remained a mystery. The clin-
ical impression that many SHR patients have undergone
extensive cardiological tests due to chest discomfort and
pain without evident results illustrates the problem of SHR
misdiagnosis, which could be consistent with the present
findings. Angina in women without obstructive coronary
artery disease is also sometimes called cardiac syndrome X
(CSX) and this condition has many similarities with SHR,
though the terminology varies.48 The exact mechanism of
this syndrome is not known. Provoking a group of patients
suffering from CSX with inhaled capsaicin may reveal
further connections. The SHR patients in the current study
could also be diagnosed with chronic unexplained cough,
which is in agreement with earlier studies49 and in
concordance with the new concept of cough hypersensi-
tivity syndrome comprising a number of different “cough
labels”.6,7,50 However, no examinations regarding esopha-
geal reflux or laryngeal dysfunction were conducted, which
might have provided valuable information, especially in the
patients with SHR.
We conclude that the lower airways and chest symptoms
that patients with SHR experience can be in part explained
by an increased respiratory rate and impaired respiratory
movement. We hypothesize that both the increased pain
sensitivity as well as the earlier known augmented capsa-
icin cough sensitivity may origin in a general “up-regula-
tion” of the TRP receptors of sensory nerves followed by
lowered pain thresholds, developing into muscle tension
and decreased chest mobility in a “vicious circle”. That
a younger group of SHR patients is comparable with an
older group of patients with mainly severe or very severe
COPD in several aspects may illustrate the problems that
SHR patients face. The current findings of dysfunctional
breathing related to the mostly unexplained symptoms of
SHR may be followed by novel treatment possibilities. It is
a future challenge to see whether structured physiotherapy
can help these patients to break the circle of symptoms,
tension and pain and improve their dysfunctional breathing
and chest mobility.Conflict of interest statement
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